Zoetis Inc. (ZTS) company profile
Close on Nov 17, 2026Market cap $34.50BP/E 13.7Yield 2.43%
About Zoetis
Pharmaceutical Preparations, SIC 2834
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, diagnostic products, and precision animal health solutions. The enterprise organizes operations into United States and International segments, offering therapies across companion animals and livestock. Core categories include parasiticides, dermatology, vaccines, anti-infectives, and pain management products, alongside diagnostics and genetic tests. The company serves veterinarians, livestock producers, and pet owners through direct sales, veterinary distributors, retail pharmacies, and e-commerce channels.
Headquartered in Parsippany, New Jersey, the company markets products directly in approximately 45 countries and sells into more than 100 countries across North America, Europe, Africa, Asia, Australia, and South America. Its operational footprint features a dedicated research and development headquarters in Kalamazoo, Michigan, and a network of 21 company-operated manufacturing sites across multiple continents, supplemented by more than 90 contract manufacturing organizations. The enterprise maintains global operations supported by approximately 3,900 sales and technical personnel and 1,700 research and development staff.
Summary of the business section of Zoetis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Zoetis Inc.
- Founded
- 2012
- Headquarters
- Parsippany, NJ
- Address
- 10 Sylvan Way 07054
- Phone
- (973) 822-7000
- Website
- www.zoetis.com
- Employees
- 14,500, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Short Hills, NJ
Stock & identifiers
- Ticker
- ZTS
- Exchange
- NYSE
- IPO date
- Feb 4, 2013
- Shares outstanding
- 413M, Jul 31, 2026
- Public float
- $69.23B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1555280
- CUSIP
- 98978V103
- ISIN
- US98978V1035
- FIGI
- BBG0039320N9
- Share class FIGI
- BBG0039320P7
- LEI
- 549300HD9Q1LOC9KLJ48
- EIN
- 46-0696167
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kristin C. Peck | Chief Executive Officer, Director | 105,902 |
| Kevin Esch | Executive Vice President | 702 |
| Keith Sarbaugh | Executive Vice President | 3,346 |
| Abhay U. Nayak | Executive Vice President | 0 |
| Julie Fuller | Executive Vice President | 1,588 |
| Roxanne Lagano | Executive Vice President | 16,466 |
| Astorga Jeannette Ferran | Executive Vice President | 1,874 |
| Rimma Driscoll | Executive Vice President | 5,894 |
| James Saccaro | EVP, CFO & COO | 0 |
| Wetteny Joseph | Chief Financial Officer | 22,816 |
| Jamie Brannan | Executive Vice President | 4,301 |
| Nicholas Ashton | Executive Vice President | 2,214 |
| Robert J. Polzer | Executive Vice President | 5,208 |
| Mark Stetter | Director | 1,572 |
| Frank A. Damelio | Director | 21,458 |
| Michael B. McCallister | Director | 31,893 |
| Louise M. Parent | Director | 18,208 |
| Paul Bisaro | Director | 27,862 |
| Gregory Norden | Director | 18,167 |
| Khosla Sanjay | Director | 1,892 |
| Gavin Hattersley | Director | 3,354 |
| Vanessa Broadhurst | Director | 3,920 |
| Willie M. Reed | Director | 12,864 |
| Antoinette Renee Leatherberry | Director | 5,280 |
| Stephanie Tilenius | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $19.05M | $2.77M | $4.02M | $80 | $188 |
| FY2024 | $17.21M | $759.62K | $3.35M | $102 | $148 |
| FY2023 | $15.24M | $26.37M | $2.99M | $122 | $137 |
| FY2022 | $14.00M | -$15.71M | $2.93M | $90 | $136 |
| FY2021 | $13.10M | $33.52M | $4.46M | $148 | $126 |
| FY2020 | $10.37M | $15.56M | $3.76M | $126 | $108 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Kristin C. Peck Chief Executive Officer | $1.35M | $10.22M | $3.41M | $2.19M | $1.88M | $19.05M | +11% |
| Wetteny Joseph Executive Vice President (“EVP”) and Chief Financial Officer | $800.00K | $2.85M | $949.96K | $832.00K | $164.94K | $5.60M | +10% |
| Jamie Brannan EVP and Chief Commercial Officer | $720.00K | $1.67M | $557.99K | $673.92K | $348.53K | $3.97M | +31% |
| Robert J. Polzer Former EVP and President of Research and Development | $710.00K | $1.67M | $555.46K | $590.72K | $144.72K | $3.67M | +23% |
| Roxanne Lagano EVP, General Counsel and Corporate Secretary | $700.00K | $1.04M | $347.50K | $604.80K | $130.79K | $2.83M | +8% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 4, 2013
- Offer price
- $26.00
- Securities offered
- 86,100,000
- Gross proceeds
- $2.24B
- Exchange
- NYSE
- First trading day
- Feb 1, 2013
- First-day close
- $31.01+19.3%
- Lock-up ends (est.)
- Jul 31, 2013
“Our Class A common stock has been approved for listing on the New York Stock Exchange, or NYSE, under the symbol “ZTS.” The initial public offering price is $26.00 per share of Class A common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 14,500 employees worldwide, which included approximately 6,800 employees in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 31, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 10, 2015 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 17, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 13, 2013 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 22, 2013 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 4, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 29, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?